Old Web
English
Sign In
Acemap
>
authorDetail
>
Nathan G. Hatcher
Nathan G. Hatcher
Merck & Co.
Neurodegeneration
Biology
Diabetes mellitus
LRRK2
Molecular biology
3
Papers
31
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Using measures of metabolic flux to align screening and clinical development: Avoiding pitfalls to enable translational studies
2021
Santhosh Satapati
Daniel P Downes
Daniel Metzger
Harish Shankaran
Saswata Talukdar
Yingjiang Zhou
Zhao Ren
Michelle Chen
Yeon-Hee Lim
Nathan G. Hatcher
Xiujuan Wen
Payal R. Sheth
David G. McLaren
Stephen F. Previs
Show All
Source
Cite
Save
Citations (0)
A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy.
2021
Neurobiology of Disease
Mali Cosden
Sarah Jinn
Lihang Yao
Cheryl A. Gretzula
Monika Kandebo
Dawn Toolan
Nathan G. Hatcher
Lei Ma
Wei Lemaire
Gregory C. Adam
Christine Burlein
Christina Minnick
Rose B. Flick
Marla L Watt
James Mulhearn
Mark E. Fraley
Robert E. Drolet
Jacob Marcus
Sean M. Smith
Show All
Source
Cite
Save
Citations (0)
LRRK2 inhibition prevents endolysosomal deficits seen in human Parkinson's disease
2019
Neurobiology of Disease
Emily M. Rocha
Briana R. De Miranda
Sandra L. Castro
Robert E. Drolet
Nathan G. Hatcher
Lihang Yao
Sean M. Smith
Matthew T. Keeney
Roberto Di Maio
Julia Kofler
Teresa G. Hastings
J. Timothy Greenamyre
Show All
Source
Cite
Save
Citations (31)
1